The American Heart Association and American College of Cardiology Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease.
The American Heart Association (AHA) and American College of Cardiology (ACC) Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease. The new guidelines are available in Circulation and the Journal of the American College of Cardiology.
They update 2006 guidelines on secondary prevention and add risk-factor reduction “because important evidence from clinical trials has emerged that further supports and broadens the merits of intensive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease (including peripheral artery disease),” according to the writing committee.
The guideline’s foundation continues to be patient behavior, including physical exercise, smoking cessation, and avoidance of second-hand smoke, and weight management. The guidelines recommend patients participate in at least 30 minutes of physical activity every day.
“Unless improvements are made in behavior and medical therapy, the same blood vessel problem that caused [the] first heart attack or stroke can occur again – and may result in death – so long-term changes need to be initiated to get the vascular disease under control,” said Sidney C. Smith Jr, MD, chair of the guideline writing group and professor of medicine at the University of North Carolina.
The guidelines include a new recommendation emphasizing the importance of referring patients for cardiac rehabilitation, and they include sections on other often-overlooked factors that can influence patients’ outcomes, such as depression and flu shots.
AHA and ACC Foundation released the guidelines even though they are waiting for the new Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) guidelines and new Adult Treatment Panel 4 (ATP 4) guidance on lipid management. The National Heart, Lung, and Blood Institute projects those guidelines won’t be available until 2012.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.